References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2024 · External reference

Epidemiology, screening, and prevention of bladder cancer

10.1016/j.euo.2022.10.003 · 2022 · External reference

Advances in diagnosis and treatment of bladder cancer

10.1136/bmj-2023-076743 · 2024 · External reference

European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update

10.1016/j.eururo.2024.07.027 · 2024 · External reference

Bladder cancer, version 3.2024

10.6004/jnccn.2024.0024 · 2024 · External reference

Real world outcomes of patients with bladder cancer

10.1016/j.hoc.2021.01.005 · 2021 · External reference

Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis

10.1016/j.ijrobp.2016.11.056 · 2017 · External reference

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2023 Guidelines

10.1016/j.eururo.2023.08.016 · 2024 · External reference

The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives

10.1016/j.ctrv.2022.102351 · 2022 · External reference

10.1038/sj.onc.1210477

10.1038/sj.onc.1210477 · External reference

10.1056/nejmcibr1909386

10.1056/nejmcibr1909386 · External reference

10.1126/science.3798106

10.1126/science.3798106 · External reference

HER2 expression in urothelial carcinoma, a systematic literature review

10.3389/fonc.2022.1011885 · 2022 · External reference

10.1016/j.euf.2016.06.007

10.1016/j.euf.2016.06.007 · External reference

Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases

10.1016/j.humpath.2016.07.014 · 2016 · External reference

Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder

2019 · External reference

New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer

10.3390/ijms22179644 · 2021 · External reference

10.1056/nejmoa1914609

10.1056/nejmoa1914609 · External reference

Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates

10.3390/ijms232012659 · 2022 · External reference

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

10.1158/1078-0432.ccr-20-2488 · 2021 · External reference

Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer

10.1056/nejmoa2407086 · 2024 · External reference

A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma

2022 · External reference

10.1200/jco.22.02864

10.1200/jco.22.02864 · External reference

10.1016/j.ctrv.2022.102436

10.1016/j.ctrv.2022.102436 · External reference

10.1038/bjc.2015.435

10.1038/bjc.2015.435 · External reference

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours

10.1016/j.eururo.2011.05.035 · 2011 · External reference

Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy

10.1080/2090598x.2020.1814183 · 2020 · External reference

Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer

2023 · External reference

Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy

10.1038/srep42713 · 2017 · External reference

10.1038/modpathol.2013.135

10.1038/modpathol.2013.135 · External reference

10.1111/bju.15006

10.1111/bju.15006 · External reference

Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study

10.1200/jco.2023.41.16_suppl.4566 · 2023 · External reference

Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer

10.1309/ajcp4a7ktayhzsoe · 2013 · External reference

Targeting HER2 heterogeneity in breast and gastrointestinal cancers

2023 · External reference

Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer

10.1016/j.prp.2020.153229 · 2020 · External reference

Computer-aided detection and prognosis of colorectal cancer on whole slide images using dual resolution deep learning

10.1007/s00432-022-04435-x · 2022 · External reference

MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer

10.1016/j.ebiom.2020.103042 · 2020 · External reference

A deep learning quantification algorithm for HER2 scoring of gastric cancer

2022 · External reference

What is the added value of digital image analysis of HER 2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms

10.1111/his.13812 · 2019 · External reference

Unresolved reference

2022 · External reference

10.1007/s10549-015-3475-3

10.1007/s10549-015-3475-3 · External reference

ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry

10.1111/j.1365-2559.2011.04142.x · 2012 · External reference

10.1109/tkde.2009.191

10.1109/tkde.2009.191 · External reference

MS. end-to-end deep learning fusion of fingerprint and electrocardiogram signals for presentation attack detection

10.3390/s20072085 · 2020 · External reference

Unresolved reference

2022 · External reference

Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials

2023 · External reference

HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study

10.1007/s00262-023-03419-1 · 2023 · External reference

Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2-low breast cancer

10.1111/his.14877 · 2023 · External reference

Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies

10.1016/j.compmedimag.2023.102270 · 2023 · External reference

HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues

10.1111/his.13333 · 2017 · External reference

HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH

10.1016/j.anndiagpath.2019.151451 · 2020 · External reference

The role of artificial intelligence in accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in breast cancer

10.1016/j.modpat.2022.100054 · 2023 · External reference

10.1309/ajcpcx69hgddgycq

10.1309/ajcpcx69hgddgycq · External reference

HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population

10.1093/oncolo/oyad070 · 2023 · External reference